ACOSOG Z1031: A randomized phase II trial comparing exemestane, letrozole, and anastrozole in postmenopausal women with clinical stage II/III estrogen receptor-positive breast cancer

被引：6
|
作者：
Ellis, M. J.
Babiera, G.
Unzeitig, G. W.
Marcom, P. K.
Guenther, J. M.
Deshryver, F. K.
Allred, D. C.
Suman, V.
Hunt, K.
Olson, J. A.
机构：
[1] Washington Univ, Siteman Canc Ctr, St Louis, MO USA
[2] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[3] Doctors Hosp Laredo, Laredo, TX USA
[4] Duke Univ, Med Ctr, Durham, NC USA
[5] Good Samaritan Hosp, Cincinnati, OH USA
[6] Mayo Clin, Rochester, MN USA
[7] Duke Univ, Ctr Canc, Durham, NC USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2010年 / 28卷 / 18期
关键词：
D O I：
10.1200/jco.2010.28.18_suppl.lba513
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
LBA513
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Local-Regional Recurrence After Neoadjuvant Endocrine Therapy: Data from ACOSOG Z1031 (Alliance), a Randomized Phase 2 Neoadjuvant Comparison Between Letrozole, Anastrozole, and Exemestane for Postmenopausal Women with Estrogen Receptor-Positive Clinical Stage 2 or 3 Breast Cancer
    Kelly K. Hunt
    Vera J. Suman
    Hannah F. Wingate
    A. Marilyn Leitch
    Gary Unzeitig
    Judy C. Boughey
    Funda Meric-Bernstam
    Matthew J. Ellis
    John Olson
    [J]. Annals of Surgical Oncology, 2023, 30 : 2111 - 2118
  • [2] Local-Regional Recurrence After Neoadjuvant Endocrine Therapy: Data from ACOSOG Z1031 (Alliance), a Randomized Phase 2 Neoadjuvant Comparison Between Letrozole, Anastrozole, and Exemestane for Postmenopausal Women with Estrogen Receptor-Positive Clinical Stage 2 or 3 Breast Cancer
    Hunt, Kelly K. K.
    Suman, Vera J. J.
    Wingate, Hannah F. F.
    Leitch, A. Marilyn
    Unzeitig, Gary
    Boughey, Judy C. C.
    Meric-Bernstam, Funda
    Ellis, Matthew J. J.
    Olson, John
    [J]. ANNALS OF SURGICAL ONCOLOGY, 2023, 30 (04) : 2111 - 2118
  • [3] ASO Visual Abstract: Local-Regional Recurrence Following Neoadjuvant Endocrine Therapy - Data from ACOSOG Z1031 (Alliance), a Randomized Phase II Neoadjuvant Comparison Between Letrozole, Anastrozole, and Exemestane for Postmenopausal Women with Estrogen Receptor-Positive Clinical Stage 2-3 Breast Cancer
    Hunt, Kelly K. K.
    Suman, Vera J. J.
    Wingate, Hannah F. F.
    Leitch, A. Marilyn
    Unzeitig, Gary
    Boughey, Judy C. C.
    Meric-Bernstam, Funda
    Ellis, Matthew J. J.
    Olson, John A. A.
    [J]. ANNALS OF SURGICAL ONCOLOGY, 2023, 30 (04) : 2119 - 2120
  • [4] ASO Visual Abstract: Local-Regional Recurrence Following Neoadjuvant Endocrine Therapy – Data from ACOSOG Z1031 (Alliance), a Randomized Phase II Neoadjuvant Comparison Between Letrozole, Anastrozole, and Exemestane for Postmenopausal Women with Estrogen Receptor–Positive Clinical Stage 2–3 Breast Cancer
    Kelly K. Hunt
    Vera J. Suman
    Hannah F. Wingate
    A. Marilyn Leitch
    Gary Unzeitig
    Judy C. Boughey
    Funda Meric-Bernstam
    Matthew J. Ellis
    John A. Olson
    [J]. Annals of Surgical Oncology, 2023, 30 : 2119 - 2120
  • [5] Randomized Phase II Neoadjuvant Comparison Between Letrozole, Anastrozole, and Exemestane for Postmenopausal Women With Estrogen Receptor-Rich Stage 2 to 3 Breast Cancer: Clinical and Biomarker Outcomes and Predictive Value of the Baseline PAM50-Based Intrinsic Subtype-ACOSOG Z1031
    Ellis, Matthew J.
    Suman, Vera J.
    Hoog, Jeremy
    Lin, Li
    Snider, Jacqueline
    Prat, Aleix
    Parker, Joel S.
    Luo, Jingqin
    DeSchryver, Katherine
    Allred, D. Craig
    Esserman, Laura J.
    Unzeitig, Gary W.
    Margenthaler, Julie
    Babiera, Gildy V.
    Marcom, P. Kelly
    Guenther, Joseph M.
    Watson, Mark A.
    Leitch, Marilyn
    Hunt, Kelly
    Olson, John A.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (17) : 2342 - 2349
  • [6] Efficacy of Alternative Dose Regimens of Exemestane in Postmenopausal Women With Stage 0 to II Estrogen Receptor-Positive Breast Cancer A Randomized Clinical Trial
    Serrano, Davide
    Gandini, Sara
    Thomas, Parjhitham
    Crew, Katherine D.
    Kumar, Nagi B.
    Vornik, Lana A.
    Lee, J. Jack
    Veronesi, Paolo
    Viale, Giuseppe
    Guerrieri-Gonzaga, Aliana
    Lazzeroni, Matteo
    Johansson, Harriet
    D'Amico, Mauro
    Guasone, Flavio
    Spinaci, Stefano
    Bertelsen, Bjorn-Erik
    Mellgren, Gunnar
    Bedrosian, Isabelle
    Weber, Diane
    Castile, Tawana
    Dimond, Eileen
    Heckman-Stoddard, Brandy M.
    Szabo, Eva
    Brown, Powel H.
    DeCensi, Andrea
    Bonanni, Bernardo
    [J]. JAMA ONCOLOGY, 2023, 9 (05) : 664 - 672
  • [7] Pharmacoeconomic analysis of adjuvant therapy with exemestane, anastrozole, letrozole or tamoxifen in postmenopausal women with operable and estrogen receptor-positive breast cancer
    Gil J.M.
    Rubio-Terrés C.
    del Castillo-Saiz A.
    González P.
    Canorea F.
    [J]. Clinical and Translational Oncology, 2006, 8 (5) : 339 - 348
  • [8] Exemestane as primary treatment of oestrogen receptor-positive breast cancer in postmenopausal women: a phase II trial
    Barnadas, A.
    Gil, M.
    Gonzalez, S.
    Tusquets, I.
    Munoz, M.
    Arcusa, A.
    Prieto, L.
    Margeli-Vila, M.
    Moreno, A.
    [J]. BRITISH JOURNAL OF CANCER, 2009, 100 (03) : 442 - 449
  • [9] Exemestane as primary treatment of oestrogen receptor-positive breast cancer in postmenopausal women: a phase II trial
    A Barnadas
    M Gil
    S González
    I Tusquets
    M Muñoz
    A Arcusa
    L Prieto
    M Margelí-Vila
    A Moreno
    [J]. British Journal of Cancer, 2009, 100 : 442 - 449
  • [10] Phase II, Randomized Trial to Compare Anastrozole Combined with Gefitinib or Placebo in Postmenopausal Women with Hormone Receptor-Positive Metastatic Breast Cancer
    Cristofanilli, Massimo
    Valero, Vicente
    Mangalik, Aroop
    Royce, Melanie
    Rabinowitz, Ian
    Arena, Francis P.
    Kroener, Joan F.
    Curcio, Elizabeth
    Watkins, Claire
    Bacus, Sarah
    Cora, Elsa M.
    Anderson, Elizabeth
    Magill, Patrick J.
    [J]. CLINICAL CANCER RESEARCH, 2010, 16 (06) : 1904 - 1914
12345